Ann: ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order, page-25

Before you get too excited, maybe look back at the last set of accounts (for EOY 2022) - these cover the forst half of the financial year.

Net loss for the six month period was $10mil and the asset value per share declined from .75 cents down to .1 cent.

MXC will need to expand it sales revenue fairly dramatically. Not sure what the profit margin would be but maybe in the range of 33%. $2mil is revenue is around $600k - not much of a dent in $20mil in losses for the year. They would have to increase revenue (which was about $2mil before this announcement) maybe 10 fold to bring them into a profit situation.

Plus, they now have more debt to service which will increase the financial pressure on MXC.

An 86% SP rise will always be celebrated from shareholders, it is how long the SP can be sustained that will matter. Maybe wise to keep comments in the neutral zone and your feet firmly planted on the ground for the next month and see where things are at then.